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second-line group had 67 AECB episodes (cephradine (n=3), cefuroxime (n=23), cefaclor (n=39), and cefprozil (n=2)); and the third-line group consisted of 57 AECB episodes (co-amoxiclav (n=15), azithromycin (n=22), and ciprofloxacin (n=20)).
Study design
This was a retrospective cohort study, carried out in a single centre. The duration of the follow-up in terms of mean (SD) time until next AECB treatment ranged from 17.1 (22) weeks to 34.3 (35.5) weeks. Loss to follow-up was not reported. The consensus of resident pulmonologists was the main reference source for the classification of the antimicrobial agents.
Analysis of effectiveness
The principle (intention to treat or treatment completers only) used in the analysis of effectiveness was not explicitly specified. The clinical outcome measures were failure rate within 14 days of initiation of antimicrobial therapy, the number of cases hospitalised within 2 weeks for failed patients, the duration of antibiotic therapy, and the time until the next AECB treatment. The antibiotic groups were reported to be comparable in terms of vital signs, pulmonary function tests, and spirometry. Severity of disease, as measured by pulmonary function tests (PFTs) or spirometry, was treated as the covariate in the analysis of variance (ANOVA).
Effectiveness results
The effectiveness results were as follows:
Failure rate within 14 days of initiation of antimicrobial therapy for the whole study sample was 15.2% (34 of 224). This was broken down into 19% (19 of 100) for the first-line agents, 16.4% (11 of 67) for the second-line agents, and 7% (4 of 57) for the third-line agents (p<0.05 for the difference between first-line and third-line agents).
The total hospitalisation rate within 2 weeks for failed patients was 76% (26 of 34). This was broken down into 18 cases receiving first-line agents (18% in terms of the first-line group's sample size), 5 cases in the second-line group (7% in terms of the second-line group's sample size), and 3 cases receiving third-line agents (5% in terms of the thirdline group's sample size) (p<0.02 for the difference between first-line and third-line agents and p<0.054 for the difference between second-line and third-line agents).
The first-line group had a mean (SD) duration of antibiotic therapy of 8.9 (3.3) days of therapy versus 8.3 (2.3) days in the second-line group, and 7.5 (2.5) days in the third-line group (p<0.02 for the difference among the three groups).
